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Abstract
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major
complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-
interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive
immunosuppression it should not be given to stable or non-progressing disease. The correct identification
of disease with high risk of progression remains a challenge for early therapeutic intervention, and bio-
markers remain urgently needed. In fact, eight categories of biomarkers have been identified and classi-
fied according to the different biological pathways involved. The purpose of this article is to describe the
main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-
interstitial lung disease.
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Rheumatology key messages
. Interstitial lung disease is a frequent complication of SSc and its main cause of death.
. The correct identification of SSc-associated interstitial lung disease with high risk of progression remains a
challenge.
. In SSc-associated interstitial lung disease, biomarkers are needed to aid clinical decisions for therapeutic inter-
vention and follow-up.
Introduction
SSc is a rare inflammatory disease of unknown origin
associated with multi-organ involvement. One of the
major complications that drives the mortality of SSc
patients is interstitial lung disease (ILD) [1]. The typical
physiopathological pattern associates vascular inflam-
mation and fibrosing process [2]. The main clinical clas-
sification is based on skin fibrosis extension. lcSSc is
characterized by a skin fibrosis restricted to distal
areas to the elbows and knees. By contrast, dcSSc in-
volves proximal areas, the face and the trunk, in addition
to distal areas. Furthermore, internal organs (kidney,
lungs, heart, etc.) are more frequently affected in this
disease subtype. Like other connective tissue diseases,
SSc is associated with autoantibody positivity (ANA).
The implication of ANA in disease physiopathology is
not yet fully understood, but they are associated with
specific phenotypes. The course of SSc-associated
interstitial lung disease (SSc-ILD) progression has a
wide spectrum, ranging from slow-evolving disease to
quick flare-up and deterioration. Since the treatment is
based on aggressive immunosuppression it should not
be given to patients with a stable and non-progressing
disease. The problem, as in other ILDs [35], is to identify
patients at high risk of progression for early therapeutic
intervention [6, 7].
Biological markers, often referred to as biomarkers, are
commonly defined as objectively measured elevated
indicators of physiological/pathological processes or
pharmacological response to therapeutic intervention [3,
8]. Biomarkers remain urgently needed as tools for differ-
ential diagnosis, prognosis and disease progression, and
as therapeutic response predictors in SSc-ILD. Although
ANA were the first biomarkers available in SSc, they still
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are unhelpful for the assessment of disease activity and
treatment response [9, 10].
Ideally, for widespread utility, biomarkers should be
easy to sample and analyse [3]. Therefore, we focused
our review on blood molecules and circulating cells avail-
able in SSc-ILD to aid health care providers in clinical
decisions and patients’ follow-up.
Here we have performed a systematic research in
PubMed by typing the words ‘biomarkers’ and ‘systemic
sclerosis’, and selecting those measured in blood.
Publications dates of selected papers range from 1993
up to 2019. Papers were selected according to their po-
tential clinical utility.
We divided biomarkers into eight different categories
(Table 1), according to their involvement in distinct biolo-
gical process. Furthermore, we suggest the main clinically
relevant biomarkers according to our literature review
(Table 2).
Alveolar epithelial proteins
Alveolar epithelial biomarkers are easily identified be-
cause of their high turnover, but also due to the central
role of epithelial cells. Nevertheless, the markers of alveo-
lar epithelial cell lesions lack specificity and are modified
in a broad range of diseases. The main biomarkers asso-
ciated with alveolar epithelial cell damage (or dysfunction)
are the Krebs von den Lungen-6 (KL-6) antigen and the
surfactant proteins A and D (SP-A and SP-D).
SP-A and SP-D
Pulmonary surfactant proteins are lipoproteins secreted
by alveolar epithelial and Clara cells. They are implicated
in reducing the alveolar surface tension at the airliquid
interface to prevent small airway collapse. These proteins
are pneumo-specific [3, 11] and the serum value is asso-
ciated with the damage extent of the capillaryalveolar
barrier (with a leak to the blood compartment).
SP-D is increased in patients with SSc-ILD compared
with healthy subjects [1215, 71]. Serum SP-D is higher in
patients with SSc-ILD than in SSc patients without ILD
[13, 16]. Due to the small sample size and population het-
erogeneity in previous studies, there were some discre-
pancies regarding the diagnostic and prognostic value of
SP-D in SSc-ILD [12, 14, 15, 1719, 72]. Recently, the
largest prospective cohort evaluating SP-D in SSc was
published (n= 427). In this large study, serum SP-D
value combined with serum anti-topoisomerases I anti-
body could detect patients with SSc-ILD with 97% sensi-
tivity, 69% specificity, an 80% positive predictive value
and a 95% negative predictive value. Furthermore, with
the association of these two biomarkers, three categories
of patient could be identified according to their risk of ILD
(mild risk 3044%; moderate risk 4570% and high risk
>70%). Nevertheless, SP-D was correlated neither to the
severity of the lung impairment, nor to its evolution or
patient mortality [16]. Interestingly, a recent short
retrospective study (n= 32) found that a rapid decrease
in serum SP-D after CYC and prednisolone treatment
(below 200 ng/ml) was predictive of good response to
treatment [20]. This result needs further investigation in
large scale prospective trials. According to these results,
SP-D seems to be a good biomarker for SSc-ILD diagno-
sis, but not for severity or prognosis evaluation.
Concerning the therapeutic response evaluation and pre-
diction, large scale prospective studies are necessary.
Focusing on SP-A, which is known to be also asso-
ciated with alveolar epithelial damage, many authors
agreed that its sensitivity (around 45%) and specificity is
hardly lower than SP-D in the context of SSc-ILD [11].
KL-6
KL-6 is a high molecular weight glycoprotein produced by
type II pneumocytes and bronchial epithelial cells [73]. Its
production is raised during epithelial lesions and cellular
regeneration [22]. In normal lungs, this glycoprotein is
involved in fibroblast stimulation and apoptosis inhibition
[74]. In case of epithelial lesion, alveolo-capillary leak can
occur and leads to an increase of serum KL-6 levels.
Indeed, this modulation is not specific to SSc and can
be found in numerous other diseases associated with
alveolar epithelial cells lesions (autoimmune diseases, ra-
diation-associated pneumonia, drug-associated pneumo-
nia, etc.) [23, 71, 73, 75, 76]. In SSc-ILD, KL-6 serum
levels could be of interest for diagnosis and prognosis,
and for therapeutic response evaluation.
As already mentioned, KL-6 is not specific to SSc-ILD
and is known to be increased in patients with active fibros-
ing lung disease [22, 24]. In SSc-ILD patients, former small
studies identified a KL-6 serum value of 500 U/ml to diag-
nose SSc-ILD with a 93% diagnostic accuracy at sensitivity
and specificity of 79 and 93%, respectively [25, 75].
However, a recent large prospective study (n= 427) in SSc
patients found a sensitivity of only 44% and a specificity of
85% (with negative and positive predictive values of 75 and
54%, respectively) for a cut-off serum value of 923 U/ml [16].
Once the diagnosis is made, KL-6 serum level can help in
disease severity evaluation since it is negatively correlated
with lung function [assessed by forced vital capacity (FVC)
and lung diffusion capacity for carbon monoxyde (DLCO)]
and positively with radiological impairment or presence of
extensive lung fibrosis [16, 20, 2224]. These results were
recently confirmed in the largest prospective SSc-ILD
cohort evaluating KL-6 so far [16]. Otherwise, a serum
level >1000 U/ml in patients suffering from ILD (various
aetiologies considered) was associated with an increased
mortality at 5 years [26], and Kuwana et al. identified that a
serum level >1273 U/ml was found in patients with end-
stage SSc-ILD [21]. Unfortunately, the recent large pro-
spective cohort did not confirm the correlation of KL-6
with mortality or with the prognosis [16]. Finally, for some
authors, serum level variations were associated with modi-
fication of the disease activity (flare-ups or improvements).
Furthermore, a serum level >2000 U/ml in patients under
treatment (corticoids and CYC) predicted poor therapeutic
response in a small retrospective study [20, 24, 27].
Taken together, these results suggest that KL-6 could
be a good biomarker to assess SSc-ILD severity, but not
2 https://academic.oup.com/rheumatology
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for diagnosis or prognosis. Concerning the therapeutic
response prediction, more studies are necessary.
Chemokines and cytokines
CCL18
Chemokine ligand 18 (CCL18) is a constitutive chemokine
produced by antigen-presenting cells (mainly dendritic cells
and macrophages) in the lung. While the role of CCL18 is
not yet fully understood, this molecule seems to be mainly
involved in cellular trafficking and in immune response
modulation [77]. Moreover, CCL18 is involved in multiple
lung fibrosing diseases including SSc-ILD (hypersensitivity
pneumonia, sarcoidosis and idiopathic lung fibrosis) [77].
In SSc, CCL18 acts by driving fibroblast proliferation and
collagen production. As a positive feedback, native colla-
gen increases CCL18 production, leading to a self-sustain-
ing loop involved in pulmonary fibrosis [78]. In some
studies, CCL18 has been found to be inversely correlated
with pulmonary function [total lung capacity (TLC), FVC and
DLCO] [77]. The first published of them, performed with 85
patients followed during 3.7 years, showed that elevated
serum values (cut-off 187 ng/ml) are associated with
worse pulmonary functional impairment and higher mortal-
ity [hazard ratio (HR) = 5.36] [29]. Similarly, a cut-off value of
140 ng/ml was discriminating on mortality and pulmonary
functional impairment in another study [30]. In a third study,
serum CCL18 >53 ng/ml was also associated with a more
progressive lung disease based on pulmonary function
tests and radiological extension of fibrosis [31]. These re-
sults were recently sustained by a large prospective trial
(n= 427) showing that a high baseline CCL18 serum value
(cut-off 84 pg/ml) (HR = 2.9) and male sex (HR = 2.48) were
the best predictors of lung function decline during follow-up
[16]. Unfortunately, this study did not confirm the correl-
ation with mortality. Taken together, these results suggest
that CCL18 is a really interesting biomarker with which to
assess the prognosis of SSc-ILD [32], and maybe to predict
disease severity and survival.
CCL2
CCL2 is a chemokine mostly involved in monocyte traf-
ficking. Its inhibition stops leucocyte migration in the pres-
ence of scleroderma fibroblast in in vitro studies [79].
CCL2 is also involved in fibroblast stimulation, myofibro-
blasts differentiation, lymphocyte T trafficking and
lymphocyte Th2 phenotype polarization. CCL2 is mainly
produced by endothelial cells, monocytes and type II
pneumocytes [35, 80, 81].
Serum CCL2 is increased in cases of SSc-ILD [81, 82].
Furthermore, there is a positive correlation between CCL2
and the severity of the pulmonary impairment (assessed
by DLCO and FVC) in case of higher serum values [33, 83].
The correlation with the activity of the disease is not yet
shown, but can be assumed because of its importance for
fibrosis initiation and progression [84]. One study con-
firmed the prognostic value of CCL2 in two large inde-
pendent SSc cohorts (n= 266 and 171) in terms of
pulmonary functional decline and survival [33]. Those re-
sults have recently been confirmed in a prospective trial
with 298 patients (only abstract available), showing similar
results for patients with serum CCL2 >0.66 ng/ml [34].
CXCL10
CXCL10 is a strong chemokine for Th1, producers of IFN-g,
an important cytokine in scleroderma pathophysiology.










Restrictive lung disease (FVC <70%)
De novo extensive lung fibrosisa
DLCO <60%
Fibrosis extent on CT scan
Multiple small prospective cohorts





Serum value needs to be associated
with anti-topoisomerase antibody
status for a better diagnostic
accuracyb
Large prospective cohort (n = 423)




Serum value needs to be associated
with patient sex and immunosuppres-
sive drug use for a better prognosis
evaluationb
Small prospective studies






>8 mg/ml Multiple large prospective cohorts [57, 59]
aExtensive lung disease defined as: fibrosis extent >20% on CT-scan or fibrosis extent 1030% and FVC <70%. bAccording
to Elhai et al. [16]. CCL18: chemokine ligand 18; FVC: forced vital capacity; KL-6: Krebs Von Den Lungen 6; SP-D: surfactant
protein D; SSc-ILD: SSc-associated interstitial lung disease.
6 https://academic.oup.com/rheumatology





















 user on 18 July 2019
Higher serum values are found in SSc patients and are
associated with more frequent lung and kidney involvement
[82, 85]. Concerning prognosis, results are conflicting.
Indeed, two trials (n= 31; n= 74) found no correlation be-
tween CXCL10 and the severity of lung involvement [35,
36]. On the other hand, another retrospective study per-
formed with 143 patients showed that CXCL10 is a bio-
marker for lung disease occurrence (if absent) or
worsening (if present) [37]. Those discrepancies may be
explained by a major role of Th1 cytokine at early-stage
disease and a lesser role in late-stage disease [82].
Therefore, CXCL10 should be assessed in a prospective
study with regard to the disease duration.
YKL-40
YKL-40, a chitinase 3-like protein 1, regulates cell prolif-
eration and survival and is produced by activated macro-
phages. It acts as a growth factor for connective tissue
[86] with a promitogenic action on lung fibroblast as
described in animal models [87, 88]. Some studies noticed
higher serum values in case of SSc compared with healthy
subjects [37, 55]. One prospective study on 88 patients
showed higher serum levels in case of SSc-ILD (com-
pared with SSc without ILD). A serum value >275 mg/l
was associated with worse pulmonary involvement and
higher mortality rate [56].
MMP and tissular inhibitors of MMP
MMPs are proteolytic enzymes that are involved, with
their inhibitors, in extracellular matrix turnover [89, 90].
They are secreted by macrophages, fibroblasts and endo-
thelial cells. MMPs are balanced in their activity by
protease inhibitors called tissular inhibitors of MMPs, or
TIMPS, to maintain homeostasis in extracellular matrix
remodelling.
Serum concentrations of MMP-7 and -12 are higher in
SSc patients than in healthy subjects [38, 39, 91]. They are
found in greater serum concentrations in SSc-ILD than in
SSc without ILD. Furthermore, there is a positive correl-
ation between serum levels and the severity of the disease
[38, 39].
Converse to what is seen for MMP-7 and -12, MMP-13
serum levels are lower in SSc patients than in healthy
subjects, and are positively correlated to lung function
assessed by FVC [40].
TIMPs have not been extensively studied in SSc-ILD.
However, higher serum levels of TIMP-1 were found in
case SSc-ILD compared with healthy subjects, with a
weak correlation between TIMP-1 and the alveolo-capillar
function (assessed by DLCO) [41]. Of note, comparable
results are available for TIMP-2 [41, 42].
Biomarkers of endothelial activation
Endothelial cells are highly involved in the pathophysio-
logical process of SSc. Endothelial cell aggression leads
to cell activation and inflammatory response. Chronic in-
flammation ends in a multi-organ fibrosis, which is a key
feature of ILD.
Anti-endothelial cell antibodies are found in some SSc
patients, with a variable prevalence (2286%) depending
on detection methods and the studied population [43].
Targeted antigens are variable. Concerning SSc-ILD, al-
though some authors found more frequent anti-endothe-
lial cell antibodies positivity, others did not confirm those
results [44]. These antibodies could be the cause of endo-
thelial cell activation.
Endothelin-1 (ET-1) is a peptide with vasoconstrictive
properties produced by activated endothelial cells.
ET-1 is involved in myofibroblasts differentiation and
stimulates extracellular matrix production and deposition.
Furthermore, ET-1 is involved in fibrogenesis mechanisms
induced by TGF-b [92]. Interestingly, ET-1 is increased in
SSc both in serum and broncho-alveolar lavage [45].
Histological studies have demonstrated that patients
with SSc-ILD exhibit lung overexpression of ET-1 (alveolar
epithelium, endothelial cells of micro vessels, macro-
phages) [93]. Furthermore, affected lungs showed an
overexpression of type B endothelin receptor (the oppos-
ite of healthy lung) relative to type A receptor [93].
Clinically, serum ET-1 is not correlated to SSc-ILD se-
verity [45, 94], and treatment with ET-1 receptor antagon-
ist in SSc-ILD patients did not show any improvement of
the disease [46, 47].
Selectins are adhesion molecules. They are involved in
leucocyte trafficking and migration. Although these mol-
ecules seem to be important in SSc-ILD, only a few retro-
spective studies with discordant results are available. A
more recent study by Hasegawa et al. showed higher E-
selectins and P-selectins serum levels in SSc patients
without any correlation with lung involvement [28].
Concerning cellular adhesion molecules, soluble inter-
cellular adhesion molecule 1 (sICAM-1) showed higher
serum levels in SSc patients than in healthy subjects.
Furthermore, higher serum levels are correlated with ILD
and with its severity (FVC) until 4 years after initial evalu-
ation [28].
Soluble vascular cell adhesion molecule (sVCAM) is also
increased in SSc patients compared with healthy people,
whether an ILD is present or not [9597].
Connective tissue growth factors
TGF-b is widely known as a keystone mediator in the
fibrosing process. By binding to its receptor, TGF-b
drives myofibroblasts differentiation, stimulates extracel-
lular matrix production and inhibits metalloproteinase
production [98]. Before a recent prospective trial on
TGF-b in SSc, there were conflicting results about
serum values of this cytokine in SSc [99101]. This
recent study by Dantas et al. showed higher serum
values of TGF-b in SSc patients than in healthy sub-
jects with a positive correlation with the disease
severity (digital ulcers, more extensive skin fibrosis).
Unfortunately, it does not correlate with lung involvement
or its severity [50].
Connective tissue growth factor (CTGF) is a peptide
involved in TGF-b-induced fibrosis. CTGF stimulates myo-
fibroblasts to produce collagen 1 and fibronectin, two
https://academic.oup.com/rheumatology 7





















 user on 18 July 2019
major extracellular matrix components [102]. Saton et al.
identified that SSc-ILD patients exhibit higher CTGF
serum levels than other SSc patients, with a positive cor-
relation between serum level and the severity of the dis-
ease (lower FVC and lower DLCO) [51]. Interestingly, it
appeared that some CTGF gene polymorphisms were
associated with more frequent SSc-ILD [103, 104].
Growth differentiation factor 15 (GDF-15) is a member
of TGF-b superfamily. GDF-15 is involved in fibroblast
stimulation and in immunomodulation. Like CTGF, higher
serum levels of GDF-15 (370 pg/ml) are found in SSc-ILD,
with a negative correlation to pulmonary function tests
(DLCO and FVC), as shown in a prospective study
(n= 119). Otherwise, higher serum values at baseline
seemed to be associated with progressive lung impair-
ment, highlighting the correlation between GDF-15 and
SSc-ILD activity [5254].
Acute-phase proteins
Acute-phase proteins refer to proteins whose plasma
concentrations increase (positive acute-phase protein)
or decrease (negative acute-phase protein) >25%
during inflammation. These changes are thought to con-
tribute to host defense and other adaptive capabilities
[105, 106].
Patients with serum CRP levels >8 mg/l had more fre-
quent SSc-ILD with worse pulmonary functional impair-
ment (TLC, FVC, DLCO) and higher mortality than those
with CRP <8 mg/l [57]. Otherwise, CRP was also asso-
ciated with worse multi-organ impairment (pulmonary vas-
cular impairment, kidney, skin, etc.) and is therefore not
pneumo-specific. These results were confirmed in two
others studies [58, 59]. Interestingly, high baseline CRP
serum level was predictive of poor therapeutic response
in a small retrospective study.
IL-6 is an acute-phase pleiotropic inflammatory cyto-
kine [107]. IL-6 is produced by numerous cells (lympho-
cytes, fibroblasts, monocytes, etc.) and is involved in T
cell activation, acute-phase reaction, and haematopoietic
myeloid and megakaryocytic precursors stimulation [108].
IL-6 plays a role in SSc by increasing collagen production
through fibroblast stimulation, myofibroblasts differenti-
ation and inhibiting the secretion of metalloproteinase
[107]. Interestingly, higher serum levels of IL-6 are asso-
ciated with SSc-ILD [109111].
The prognostic value of IL-6 has been assessed in 212
SSc-ILD patients [36]. This study identified that serum
levels >7.67 pg/ml are associated with increased mortality
(HR = 2.58) at 30 months and with a worse lung functional
impairment [FVC decrease >10% (HR = 2.58) after
1 month; DLCO decrease >15% (HR = 3.2) at 1 month].
A post hoc analysis finally concluded that prognostic
power is only present for mild or early SSc-ILD (FVC
>70%) and not for patients with severe lung functional
impairment. Those observations suggest an important




In 1994, Bucala et al. found that some circulating leuco-
cytes could display some fibroblast phenotypic character-
istics, and once they had migrated to injured tissues,
behaved as them. These circulating leucocytes were
called fibrocytes [112]. From a general point of view,
some circulating progenitor cells are able to migrate in
different targeted tissues (inflammation, tissular re-
modelling or repair, etc.) and to differentiate into different
cell types with phenotypic characteristics of fibroblasts,
endothelial cells or macrophages with respect to the
local cytokine background [113, 114]. Since Bucala
et al.’s publication, several progenitor circulating cells
have been discovered. They all stem from monocytic
precursors CD14+. Although these cells actually have a
well-known physiological role (scarring, tissue repair and
remodelling, host defence, etc.), they can be involved in
different pathological processes, such as pulmonary fibro-
sis [115].
In SSc-ILD, progenitors cells migrate into the lungs be-
cause of chemotactic activity. They overexpress CXCR4,
a chemoreceptor for CXCL12, a chemokine produced by
macrophage and pneumocytes in affected spots of the
lung [61, 62]. In fact, cells of monocytic origin and produ-
cing collagen (CD14+/CD34+/col1+) are present in lungs
of SSc-ILD patients, whereas they are undetectable in
healthy subjects [61]. Once there, they take part in the
pathologic process. Serum measurement of progenitor
cells is available and can be used as a biomarker of diag-
nostic and prognostic importance. Furthermore, they are
of therapeutic interest. However, there are only a few stu-
dies about this topic.
Concerning diagnosis, blood levels of fibrocytes
(CD34+/CD45+/col1+) and circulating monocytes produ-
cing collagen are higher in SSc-ILD patients than in
healthy subjects [61, 63].
Regarding prognosis, the blood level of circulating
endothelial progenitor cells is positively correlated to the
severity of SSc-ILD [64]. Furthermore, in idiopathic pul-
monary fibrosis, patients with higher circulating levels of
fibrocytes were at increased risk of worse lung impairment
and death [62].
Currently, there is no doubt about the importance of
circulating progenitor cells in SSc physiopathology and
aetiopathogeny. However, more studies are necessary
to establish their roles with precision. Their use as bio-
markers needs to be further evaluated. In the future they
could be used as a therapeutic target.
Lymphocytes
Recent data from the literature suggest an important phy-
siopathological participation of Th in SSc-ILD.
Interestingly, Th subpopulations are different between
healthy subjects and SSc-ILD patients, but also among
SSc patients, suggesting that those subpopulations are
important for the disease physiopathology and for pheno-
typic determination. For example, patients with SSc-ILD
8 https://academic.oup.com/rheumatology
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exhibit a higher Th1/Th2 ratio (usually low in SSc) com-
pared with those with SSc without ILD (with a negative
correlation compared with FVC). Furthermore, patients
with a FVC decline >10% in 6 months have a higher
Th1/Th2 ratio than those with stable disease, establishing
a link between Th1/Th2 ratio and ILD activity [116].
Patients with anti-topoisomerase antibodies were recently
identified as being at higher risk for ILD. They also fre-
quently exhibit autoreactive T lymphocyte CD4+ against
topoisomerase. SSc-ILD patients have higher blood levels
of these autoreactive cells than SSc patients without ILD.
Furthermore, there is a positive correlation between the
blood level of these cells and ILD severity (FVC) and ac-
tivity (rate of FVC decline). This study shows that this
population of autoreactive Th is enriched in Th17 and im-
poverished in Th1 [65]. Furthermore, Th17-related cyto-
kines (IL-17 and IL-23) are associated with ILD in SSc
patients, and with its severity [117, 118]. Others have
found Th22 to be increased in the blood of SSc patients
(compared with healthy subjects). Furthermore, SSc-ILD
patients have higher blood levels of Th22 than others [66].
miRNAs
miRNAs are small (about 20 nucleotides) non-coding
RNA. By fixing mRNA, they mainly down-regulate protein
translation and they act as post-transcriptional regulators
of gene expression [119].
The physiopathological importance of miRNA is now
well established in SSc [120]. Concerning this complex
regulation, the TGF-b signalling pathway has been the
most studied [121, 122]. Although miRNA expression is
tissue-specific and cell-type-dependent, the circulating
fraction of miRNA can be used as a biomarker [123].
Numerous studies have already assessed miRNA expres-
sion at the tissular level [121, 124127], but only a few of
them have explored the blood compartment.
In SSc-ILD, miR-155 is overexpressed by circulating
mononuclear cells and shows a strong negative correl-
ation with pulmonary functional impairment (assessed by
FVC and DLCO) [67]. Interestingly, miR-29a is also
reduced in patients with SSc and is assumed to be rele-
vant as an actor in the early phase of the disease [128].
Blood levels of miR-142-3p and miR-92-a are signifi-
cantly lower in SSc than in healthy subjects, and seem
to be specific to SSc compared with other autoimmune
diseases (dermatomyositis or lupus erythematosus).
However, in SSc patients, miR-142-3p serum level is not
associated with any clinical manifestation [68, 69].
Of note, miRNA-200c is elevated in connective tissue
disease without any specificity for SSc [70].
To summarize, miRNAs seem to be involved in the
pathophysiology of SSc and could serve as biomarkers,
but also as new tools for the exploration of potential thera-
peutic targets.
Limitations
One of the limitations of our review is that we chose can-
didate biomarkers in SSc-ILD according to our thinking
and their potential usefulness. Another limitation is the
lack of longitudinal studies for some of the biomarkers,
which reduces the clinical impact of the findings. We be-
lieve that further longitudinal multicentric studies are ur-
gently needed, using single or multivariate analyses to
evaluate the real clinical impact of most of the biomarkers
as diagnostic and prognostic tools.
Conclusion
SSc is a rare inflammatory disease frequently compli-
cated by ILD, which drives mortality of the patients.
Recent advances in early diagnosis and treatment of
SSc-ILD shed light on the urgent need for biomarkers
to assess the overall risk of mortality, but also the prob-
ability of disease progression and treatment response.
So far, there is no easy-to-use biomarker to evaluate
the likelihood of ILD progression in the context of SSc.
Nevertheless, the recently published article from Elhai
et al. [16] raised the utility of dosing SP-D, KL-6 and
CCL18 in SSc-ILD diagnosis and prognosis. Further pro-
spective longitudinal trials are needed to identify bio-
markers with clinical utility and potential new
therapeutic targets in SSc-ILD.
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